تداخلات بوتالبيتال وأسبرين وكافيين وكودايين

DO NOT EXCEED RECOMMENDED DOSE Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers. (نشرة إبراتروبيوم وسالبوتامول، التحذيرات)

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. (نشرة أبروسيتينيب، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (نشرة أبيكسابان، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result… (نشرة أدرينالين، التداخلات الدوائية)

Use of methylxanthines (e.g., caffeine, aminophylline and theophylline) is not recommended in patients who experience a seizures in association with adenosine injection ( 5.6 ) (نشرة أدينوزين، التحذيرات والاحتياطات)

Excessive Use of Arformoterol Tartrate Inhalation Solution and Use with Other Long-Acting Beta2-Agonists Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة أرفورموتيرول، التحذيرات والاحتياطات)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported. (نشرة أسيتازولاميد، التحذيرات)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Alvimopan capsules are contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules [see Warnings and Precautions ( 5.3 )]. (نشرة ألفيموبان، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4) ]. (نشرة إمتريسيتابين وريلبيفيرين وتينوفوفير، التحذيرات والاحتياطات)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (نشرة أمفيتامين، موانع الاستعمال)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (نشرة أمفيتامين وديكستروأمفيتامين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

INDOCIN is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to indomethacin or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة إندوميثاسين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

SECTION OXAPROZIN CAPSULES is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to oxaprozin or any components of the drug product [see WARNINGS AND PRECAUTIONS (5.7, 5.9)] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة أوكسابروزين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (نشرة أولوباتادين، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (نشرة أولوباتادين وموميتازون، التحذيرات والاحتياطات)

Avoid co-administration of ella and drugs or herbal products such as: • barbiturates • bosentan • carbamazepine • felbamate • griseofulvin • oxcarbazepine • phenytoin • rifampin • St. (نشرة أوليبريستال، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة أوميكليدينيوم وفيلانتيرول، التحذيرات والاحتياطات)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

CALDOLOR is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to ibuprofen or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة إيبوبروفين، موانع الاستعمال)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة إيبوبروفين وفاموتيدين، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Etodolac tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة إيتودولاك، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (نشرة إيدوكسابان، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity… (نشرة إينوكسابارين، تحذير مؤطر)

• patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDS [see Warnings and Precautions (5.7 and 5.8) ] . (نشرة باراسيتامول وإيبوبروفين، موانع الاستعمال)

Nursing Mothers At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (e.g . , warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1) ] . (نشرة براسوغريل، تحذير مؤطر)

Avoid coadministration with probenecid or nonsteroidal anti-inflammatory drugs. (نشرة برالاتريكسات، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

In patients on probenecid the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد، التحذيرات)

In patients on probenecid and colchicine the use of salicylates in either small or large doses is contraindicated because it antagonizes the uricosuric action of probenecid. (نشرة بروبينيسيد وكولشيسين، التحذيرات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Nursing Mothers At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

CONTRAINDICATIONS Pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine. (نشرة بنتوكسيفيلين، موانع الاستعمال)

Benzphetamine Hydrochloride Tablets should not be used concomitantly with other CNS stimulants. (نشرة بنزفيتامين، موانع الاستعمال)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Nursing Mothers At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة بوديزونيد وفورموتيرول، التحذيرات والاحتياطات)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) (نشرة بيروكسيكام، موانع الاستعمال)

Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Do not take if you are allergic to salicylates (including aspirin) taking other salicylate products Do not use if you have an ulcer a bleeding problem bloody or black stool Ask a doctor before use if you have fever mucus in the stool Ask a doctor or pharmacist before use if you are taking any drug for diabetes gout arthritis anticoagulation (thinning the blood)… (نشرة تحت ساليسيلات البزموت، التحذيرات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

TOLECTIN should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other NSAIDs. (نشرة تولميتين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (نشرة تيربوتالين، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1) ] . (نشرة تينوفوفير، التحذيرات والاحتياطات)

Serious Gastrointestinal Reactions Serious gastrointestinal reactions, including perforation, ulceration, hemorrhage, and obstruction, some with fatal outcomes, have been reported in the postmarketing setting with the use of fumaric acid esters, including TECFIDERA, with or without concomitant aspirin use. (نشرة ثنائي ميثيل الفومارات، التحذيرات والاحتياطات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة حمض الميفيناميك، موانع الاستعمال)

…the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity… (نشرة دابيغاتران، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Diflunisal tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (نشرة ديفلونيزال، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (نشرة ديفينوكسيلات وأتروبين، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ]. (نشرة ديكستروأمفيتامين، موانع الاستعمال)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides [see Warnings and Precautions (5.1) ] Concomitant use of KEVEYIS and high dose aspirin [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS [see Warnings and Precautions… (نشرة ديكلورفيناميد، موانع الاستعمال)

ZIPSOR is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة ديكلوفيناك، موانع الاستعمال)

…defects [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] • In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.2) ] • Active gastrointestinal bleeding [see Warnings and Precautions (5.3) ] • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة ديكلوفيناك وميزوبروستول، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity… (نشرة ريفاروكسابان، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Phosphodiesterase Inhibitors Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )]. (نشرة ريوسيغوات، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (نشرة سالبوتامول، التحذيرات والاحتياطات)

Salsalate tablets, USP should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (نشرة سالسالات، موانع الاستعمال)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة سالميتيرول، التحذيرات والاحتياطات)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (نشرة سترات الحديديك، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Sulindac should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (نشرة سولينداك، موانع الاستعمال)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Serious Adverse Reactions with Concomitant Theophylline Serious and fatal reactions have been reported in patients receiving concurrent administration of ciprofloxacin and theophylline. (نشرة سيبروفلوكساسين، التحذيرات والاحتياطات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (نشرة سيتريزين، التحذيرات والاحتياطات)

Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. (نشرة سيدوفوفير، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

• History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة سيليكوكسيب، موانع الاستعمال)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فلوتيكازون وسالميتيرول، التحذيرات والاحتياطات)

Flurbiprofen tablets are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to flurbiprofen or any components of the drug product [ see Warnings and Precautions (5.7 , 5.9) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة فلوربيبروفين، موانع الاستعمال)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (نشرة فورموتيرول، التحذيرات والاحتياطات)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity… (نشرة فوندابارينوكس، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…spasms in the urinary tract collection system, inactivation of nerve and muscle cells after administration of drugs to relax the muscles (depolarization block after depolarizing muscle relaxants), in case of intoxication due to “irreversibly acting” cholinesterase inhibitors (drugs used to treat dementia), intoxication with phosphoric acid esters or barbiturates. (نشرة فيزوستيغمين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other anorectic agents or CNS stimulants • Known hypersensitivity or idiosyncratic reactions to sympathomimetics (نشرة فينديميترازين، موانع الاستعمال)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

CONTRAINDICATIONS FENOPROFEN CALCIUM is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to fenoprofen or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة فينوبروفين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Nursing Mothers At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (نشرة كوكايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Throughout this package insert, the term NSAID refers to a non-aspirin non-steroidal anti-inflammatory drug. (نشرة كيتوبروفين، تحذير مؤطر)

CONCOMITANT USE WITH NSAIDs Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects. (نشرة كيتورولاك، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (نشرة لاتانوبروست، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (نشرة ليفوثيروكسين وليوثيرونين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (نشرة ليفوسالبوتامول، التحذيرات والاحتياطات)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (نشرة ليفوسيتريزين، التحذيرات والاحتياطات)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

…respiratory depression [see Warnings and Precautions ( 5.9 ) ] Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment[see Warnings and Precautions ( 5.9 ) ] Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ) / Drug Interactions ( 7 ) ]. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، موانع الاستعمال)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (نشرة ليوثيرونين، تحذير مؤطر)

Warnings For external use only Allergy alert: do not use if you are allergic to salicylates (including aspirin) unless directed by a doctor. (نشرة منثول وساليسيلات الميثيل، التحذيرات)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Use of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE requires careful consideration of the effects on codeine, and the active metabolite, morphine. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). (نشرة مونتيلوكاست، التحذيرات والاحتياطات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma, and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors. (نشرة ميثازولاميد، التحذيرات)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (نشرة ميثامفيتامين، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Unexpectedly severe and fatal gastrointestinal toxicity can occur with concomitant administration of XATMEP (primarily at high dosage) and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions ( 7.1 )] . (نشرة ميثوتريكسات، التحذيرات والاحتياطات)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

• Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (نشرة ميثيل نالتريكسون، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). (نشرة ميزوبروستول، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة ميلوكسيكام، موانع الاستعمال)

Naproxen Suspension is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see Warnings and Precautions ( 5.7 , 5.9 ) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. (نشرة نابروكسين، موانع الاستعمال)

• History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (نشرة نابروكسين وإيزوميبرازول، موانع الاستعمال)

Nabumetone tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (نشرة نابوميتون، موانع الاستعمال)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (نشرة نالتريكسون، موانع الاستعمال)

Examples paroxetine, fluoxetine, bupropion, quinidine Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Intervention Avoid use of SYMPROIC with another opioid antagonist. (نشرة نالديميدين، التداخلات الدوائية)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (نشرة نالميفين، التحذيرات والاحتياطات)

In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. (نشرة نالوكسون، التحذيرات والاحتياطات)

…concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)… (نشرة نالوكسيغول، موانع الاستعمال)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses of other opioids (such as oxycodone, hydrocodone, oxymorphone, hydrocodone, or buprenorphine) to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. (نشرة إبتيفيباتيد، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with Adapalene Cream, 0.1%. (نشرة أدابالين، التداخلات الدوائية)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (نشرة أداليموماب، التداخلات الدوائية)

However, this is of special importance in patients at risk of or having underlying renal dysfunction and patients taking concomitant nephrotoxic agents such as cyclosporine, tacrolimus, aminoglycosides, vancomycin and non-steroidal anti-inflammatory drugs [See Adverse Reactions (6.2) and Clinical Pharmacology (12.3) ]. (نشرة أديفوفير، التحذيرات والاحتياطات)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 inhibitors: Increased risk of renal impairment. (نشرة إربيسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticoagulants Clinical Impact: Aspirin may enhance the effects of anticoagulants. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (نشرة إرلوتينيب، التحذيرات والاحتياطات)

It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving IMURAN and xanthine oxidase inhibitors because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections). (نشرة أزاثيوبرين، التداخلات الدوائية)

Cytochrome P450 3A4 Interaction The concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine,… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan,… (نشرة أزيلسارتان، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. (نشرة إستراديول ودينوجيست، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (نشرة أفاتينيب، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Theophylline: Albendazole induces cytochrome P450 1A in human hepatoma cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (نشرة ألبيندازول، التداخلات الدوائية)

Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (نشرة ألتيبلاز، التحذيرات والاحتياطات)

الجنكة بيلوبا قد تزيد خطر النزف عند تناولها مع الأدوية المضادة للتخثر أو المضادة للصفيحات. (NCCIH, Ginkgo)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (نشرة ألوبيورينول، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

…part on the activity of the RAAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or patients receiving ARB, ACEI or nonsteroidal anti-inflammatory drug (NSAID), including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors), therapy may be at particular risk for developing acute renal failure… (نشرة أليسكيرين، التحذيرات والاحتياطات)

Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate sodium greater than 10 mg and aspirin-containing products. (نشرة أليندرونات، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Individuals taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. (نشرة إمتريسيتابين وتينوفوفير، التحذيرات والاحتياطات)

• Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. (نشرة أملوديبين وأولميسارتان، التداخلات الدوائية)

Patients whose renal function may depend in part on the activity of the RAS (e.g., patients with renal artery stenosis, severe heart failure, post-myocardial infarction or volume depletion) or who are on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or ARBs may be at particular risk of developing acute renal failure on amlodipine and benazepril hydrochloride. (نشرة أملوديبين وبينازيبريل، التحذيرات والاحتياطات)

Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) : In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including valsartan, may… (نشرة أملوديبين وفالسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة أمينوفيلين، التداخلات الدوائية)

Bleeding Risk Use of concomitant AGRYLIN and aspirin increased major hemorrhagic events in a postmarketing study. (نشرة أناغريليد، التحذيرات والاحتياطات)

In patients who are elderly, volume-depleted (as on diuretic therapy), or with compromised renal function, use with NSAIDs, including selective COX-2 inhibitors, may result in deterioration of renal function, including renal failure. (نشرة إنالابريل، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Non-steroidal anti-inflammatory agents In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function. (نشرة إنالابريلات، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Upon initiation or discontinuation of RENFLEXIS in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (نشرة إنفليكسيماب، التداخلات الدوائية)

Monitor RINVOQ/RINVOQ LQ-treated patients who may be at risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis and those taking concomitant medications including NSAIDs or corticosteroids). (نشرة أوباداسيتينيب، التحذيرات والاحتياطات)

This may result in a prolonged half-life for some drugs that are also metabolized by this system (e.g., cyclosporine, theophylline/methylxanthines, warfarin) when coadministered with quinolones. (نشرة أوفلوكساسين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2 ). (نشرة أولميسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

When using KONVOMEP, consider alternative antiplatelet therapy [see Drug Interactions ( 7 ) and Clinical Pharmacology ( 12.3 )] . (نشرة أوميبرازول وبيكربونات الصوديوم، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (نشرة إيباندرونات، التداخلات الدوائية)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (نشرة إيبوبروستينول، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (نشرة إيتونوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

• Pr e ssor Effect with Concomitant Oxytocic Drugs : Pressor effect of sympathomimetic pressor amines is potentiated (5.1) (نشرة إيفيدرين، التحذيرات والاحتياطات)

The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (نشرة إيكوسابنت إيثيل، التحذيرات والاحتياطات)

…Interaction The concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin,… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة بالسالازيد، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (نشرة بروبيل ثيوراسيل، التداخلات الدوائية)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (نشرة بروموكريبتين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (نشرة بريماكين، التداخلات الدوائية)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Probenecid Carbonic Anhydrase Inhibitors Clinical Impact: Concurrent use with aspirin can lead to high serum concentrations of the carbonic anhydrase inhibitor and cause toxicity due to competition at the renal tubule for secretion. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين وأدرينالين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (نشرة بورتيزوميب، التحذيرات والاحتياطات)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect. (نشرة بيريندوبريل، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticoagulants Clinical Impact: Aspirin may enhance the effects of anticoagulants. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (نشرة بينازيبريل، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Insulin, glimepiride, glipizide Anticonvulsants Clinical Impact: Aspirin can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

When administered in combination with aspirin, tadalafil 20 mg did not prolong bleeding time, relative to aspirin alone. (نشرة تادالافيل، التحذيرات والاحتياطات)

Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (نشرة تامسولوسين، التداخلات الدوائية)

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including trandolapril, may result in deterioration… (نشرة تراندولابريل، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (نشرة تريميثوبنزاميد، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (نشرة توسيليزوماب، التداخلات الدوائية)

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] . (نشرة توفاسيتينيب، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (نشرة تولكابون، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة تيريفلونوميد، التداخلات الدوائية)

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may… (نشرة تيلميسارتان، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) (نشرة تيلميسارتان وأملوديبين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Because heparin, aspirin, or TNKase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (نشرة تينيكتيبلاز، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة ثيوفيلين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Use Reclast with caution in aspirin-sensitive patients. (نشرة حمض الزوليدرونيك، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (نشرة دروسبيرينون وإيثينيل إستراديول، التحذيرات والاحتياطات)

Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3) ]. (نشرة دوتاستيريد وتامسولوسين، التداخلات الدوائية)

Examples: Probenecid Carbonic Anhydrase Inhibitors Clinical Impact: Concurrent use with aspirin can lead to high serum concentrations of the carbonic anhydrase inhibitor and cause toxicity due to competition at the renal tubule for secretion. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Probenecid Carbonic Anhydrase Inhibitors Clinical Impact: Concurrent use with aspirin can lead to high serum concentrations of the carbonic anhydrase inhibitor and cause toxicity due to competition at the renal tubule for secretion. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (نشرة دوكسابرام، التداخلات الدوائية)

Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline. (نشرة دوكسيسيكلين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (نشرة دونيبيزيل، التحذيرات والاحتياطات)

Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (نشرة ديجوكسين، التداخلات الدوائية)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (نشرة ديسموبريسين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (نشرة ديسوجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

MOTOFEN ® may potentiate the action of barbiturates, tranquilizers, narcotics, and alcohol. (نشرة ديفينوكسين وأتروبين، التداخلات الدوائية)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (نشرة ديوتيترابينازين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Isoflurane and enflurane may also prolong the duration of action of initial and maintenance doses of Rocuronium Bromide Injection and decrease the average infusion requirement of Rocuronium Bromide Injection by 40% compared to opioid/nitrous oxide/oxygen anesthesia. (نشرة روكورونيوم، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Monitor patients using rivastigmine tartrate for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (نشرة ريفاستيغمين، التحذيرات والاحتياطات)

Coadministration of zafirlukast (40 mg/day) with aspirin (650 mg four times daily) resulted in mean increased plasma levels of zafirlukast by approximately 45%. (نشرة زافيرلوكاست، الاحتياطات)

Zileuton increases theophylline levels. (نشرة زيلوتون، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): May lead to increased risk of renal impairment. (نشرة ساكوبيتريل وفالسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Nonsteroidal Anti-inflammatory drugs (NSAIDs) monitor for hyperkalemia (7.4) (نشرة سترات البوتاسيوم، التداخلات الدوائية)

Conversely, agents such as indomethacin, probenecid and salicylates may displace sulfonamides from plasma albumin and increase the concentrations of free drug in plasma. (نشرة سلفاديازين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (نشرة سوكرالفات، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Drug Interactions As with other cephalosporins, cefotaxime may potentiate the nephrotoxic effects of nephrotoxic drugs such as aminoglycosides, NSAIDs and furosemide. (نشرة سيفوتاكسيم، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those with an increased risk for developing ulcers, e.g., those with a history of ulcer disease or patients using concurrent nonsteroidal anti-inflammatory drugs (NSAIDS). (نشرة غالانتامين، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Insulin, glimepiride, glipizide Anticonvulsants Clinical Impact: Aspirin can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Insulin, glimepiride, glipizide Anticonvulsants Clinical Impact: Aspirin can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Insulin, glimepiride, glipizide Anticonvulsants Clinical Impact: Aspirin can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

There is no clinical evidence of any additive prolongation of the bleeding time when vardenafil is administered with aspirin. (نشرة فاردينافيل، التحذيرات والاحتياطات)

• Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (نشرة فارينيكلين، التداخلات الدوائية)

Non-Steroidal Anti-Inflammatory Drug (NSAID) use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7.2 ) (نشرة فالسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (نشرة فيبوكسوستات، التحذيرات والاحتياطات)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

فيتامين هـ (E) قد يثبّط تكدّس الصفيحات والتخثر المعتمد على فيتامين ك، مما يزيد خطر النزف مع مضادات التخثر ومضادات الصفيحات. (NIH Office of Dietary Supplements, Vitamin E)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Cytochrome P450 3A4 Interaction The concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine,… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Thiopental Reconstituted vecuronium, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions such as thiopental) in the same syringe or administered simultaneously during intravenous infusion through the same needle or through the same intravenous line (see DOSAGE AND ADMINISTRATION -COMPATIBILITY ). (نشرة فيكورونيوم، الاحتياطات)

Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (نشرة فينترمين، التحذيرات والاحتياطات)

Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (نشرة فينيل أسيتات الصوديوم وبنزوات الصوديوم، التحذيرات والاحتياطات)

Pressor Effect with Concomitant Oxytocic Drugs Oxytocic drugs potentiate the increasing blood pressure effect of sympathomimetic pressor amines including BIORPHEN [see Drug Interactions (7.1) ] , with the potential for hemorrhagic stroke. (نشرة فينيليفرين، التحذيرات والاحتياطات)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ). (نشرة كانديسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (نشرة كلوبيدوغريل، التحذيرات والاحتياطات)

…Interaction The concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin,… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) (نشرة كلوريد البوتاسيوم، التداخلات الدوائية)

Non-steroidal anti-inflammatory agents including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including quinapril, may result in deterioration… (نشرة كينابريل، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Theophylline or Aminophylline In 20 healthy subjects who received multiple doses of quinine sulfate (648 mg every 8 hours x 7 days) with a single 300 mg oral dose of theophylline, the quinine mean C max and AUC were increased by 13% and 14% respectively. (نشرة كينين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Insulin, glimepiride, glipizide Anticonvulsants Clinical Impact: Aspirin can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Theophylline Clinical Impact: Increased clearance of theophylline [see Clinical Pharmacology (12.3) ] . (نشرة لانسوبرازول، التداخلات الدوائية)

Methadone Diphenylheptane opioids (e.g., methadone) have been shown in nonclinical studies to dose-dependently reduce the activation of ClC-2 by lubiprostone in the gastrointestinal tract. (نشرة لوبيبروستون، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة ليدوكايين وأدرينالين، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) (نشرة ليزينوبريل، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Additionally, in studies of another stimulant, there was slowing of the increase in height [see Adverse Reactions (6.1) ] . (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (نشرة ليفلونوميد، التداخلات الدوائية)

An initial increase in serum FT 4 is followed by return of FT 4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T 4 levels may decrease by as much as 30%. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Non-Steroidal Anti-Inflammatory Drugs The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Levofloxacin in 5% Dextrose Injection, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5.4) ]. (نشرة ليفوفلوكساسين، التداخلات الدوائية)

Other Drugs Clinical effect Concomitant use of CHCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam. (نشرة ليفونورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDS, including selective COX-2 inhibitors, with ACE inhibitors, including moexipril, may result in deterioration… (نشرة موكسيبريل، التداخلات الدوائية)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions [see Warnings and Precautions ( 5.4 ), and Patient Counseling Information ( 17 )]. (نشرة موكسيفلوكساسين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (نشرة ميتيروسين، التداخلات الدوائية)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (نشرة ميثيمازول، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: • barbiturates • bosentan • carbamazepine • felbamate • griseofulvin • oxcarbazepine • phenytoin • rifampin • St. (نشرة ميدروكسي بروجستيرون، التداخلات الدوائية)

Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (نشرة ميركابتوبورين، التداخلات الدوائية)

Nephrotoxic Agents including NSAIDs: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (نشرة ميسالازين، التداخلات الدوائية)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of mexiletine. (نشرة ميكسيليتين، التداخلات الدوائية)

…Interaction The concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin,… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Patients treated with NAMZARIC should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g., those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). (نشرة ميمانتين ودونيبيزيل، التحذيرات والاحتياطات)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate rifabutin, rufinamide, aprepitant, and products containing St. (نشرة نورجيستريل وإيثينيل إستراديول، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (نشرة نورجيستيمات وإيثينيل إستراديول، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. (نشرة نوريثيستيرون، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: barbiturates bosentan carbamazepine felbamate griseofulvin oxcarbazepine phenytoin rifampin St. (نشرة نوريثيستيرون وإيثينيل إستراديول، التداخلات الدوائية)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (نشرة نوريلجيسترومين وإيثينيل إستراديول، التداخلات الدوائية)

Aspirin Concomitant aspirin may decrease the metabolic clearance of nicotinic acid. (نشرة نياسين، التداخلات الدوائية)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

In patients given very high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently. (نشرة نيزاتيدين، التداخلات الدوائية)

The interaction with high-dose fentanyl appears to be due to the combination of nifedipine and a beta-blocker, but the possibility that it may occur with nifedipine alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. (نشرة نيفيديبين، التحذيرات)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (نشرة نينتيدانيب، التحذيرات والاحتياطات)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

• Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (نشرة هيالورونيداز، التداخلات الدوائية)

Anticoagulants Clinical Impact: Aspirin may enhance the effects of anticoagulants. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التحذيرات والاحتياطات)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Aspirin can also displace warfarin from protein binding sides, leading to prolongation of both the prothrombin time and the bleeding time. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (نشرة أتراكوريوم، التحذيرات)

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT 3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.,cyclobenzaprine, metaxalone), monoamine oxidase… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

مكملات الثوم قد تزيد خطر النزف مع مضادات التخثر مثل وارفارين. (NCCIH, Garlic)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam. (نشرة إنتاكابون، الاحتياطات)

In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. (نشرة أوبروجيبانت، التداخلات الدوائية)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

A similar association, though less marked, has been suggested for barbiturates, phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin, and tetracyclines. (نشرة إيثينوديول ثنائي الأسيتات وإيثينيل إستراديول، التداخلات الدوائية)

Table 1: Clinically Relevant Interactions with Isoproterenol Epinephrine Clinical Impact Both drugs are direct cardiac stimulants, and their combined effects may induce serious arrhythmias upon simultaneous administration. (نشرة إيزوبرينالين، التداخلات الدوائية)

Although the overall incidence of tartrazine sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. (نشرة إيزوتريتينوين، التحذيرات والاحتياطات)

John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (نشرة إيفابرادين، التداخلات الدوائية)

Antihistamines and/or aspirin have been used for most mild to moderate cases. (نشرة إيفرمكتين، التحذيرات)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (نشرة برازوسين، التداخلات الدوائية)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (نشرة بنسلين G، التداخلات الدوائية)

Narcotics: Exacerbation of bradycardia possible. (نشرة بيريدوستيغمين، التداخلات الدوائية)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

(tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity [see Contraindications ( 4 )]. (نشرة دروكسيدوبا، التحذيرات والاحتياطات)

Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. (نشرة روبيفاكايين، التداخلات الدوائية)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (نشرة ريزيدرونات، التداخلات الدوائية)

مكملات أوميغا 3 قد تطيل زمن النزف إطالة خفيفة؛ والجمع بينها وبين مضادات التخثر مثل وارفارين يستدعي المراقبة، وإن كان النزف ذو الأهمية السريرية لم يُظهَر على نحو متسق. (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (نشرة سيكلوسيليكات الزركونيوم الصوديوم، التداخلات الدوائية)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

…renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due to its indirect effect… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT 3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.,cyclobenzaprine, metaxalone), monoamine oxidase… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

…angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions. (نشرة فيناستيريد، التداخلات الدوائية)

Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential. (نشرة كاربوبروست، التحذيرات)

No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin. (نشرة كوليستيبول، التداخلات الدوائية)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (نشرة ليناليدوميد، التحذيرات والاحتياطات)

Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (نشرة ألوسيترون، التداخلات الدوائية)

…Clinically Significant Drug Interaction with TAMIFLU No dose adjustments are needed for either oseltamivir or the concomitant drug when coadministering oseltamivir with amoxicillin, acetaminophen, aspirin, cimetidine, antacids (magnesium and aluminum hydroxides and calcium carbonates), rimantadine, amantadine, or warfarin [see Clinical Pharmacology (12.3) ] . (نشرة أوسيلتاميفير، التداخلات الدوائية)

Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (نشرة دوفيتيليد، التداخلات الدوائية)

Based on these data, ISENTRESS is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or P-glycoprotein (e.g., protease inhibitors, NNRTIs, opioid analgesics, statins, azole antifungals, proton pump inhibitors and anti-erectile dysfunction agents). (نشرة رالتيغرافير، التداخلات الدوائية)

Narcotic Analgesics: methadone ↓ R(-) methadone ↓ S(+) methadone No dose adjustments are required when initiating coadministration of methadone with EDURANT or EDURANT PED. (نشرة ريلبيفيرين، التداخلات الدوائية)

In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. (نشرة سيلدينافيل، التحذيرات والاحتياطات)

…Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. (نشرة فامسيكلوفير، التداخلات الدوائية)